Attendee search 

Personalis, Inc. headquartered in Menlo Park California, USA, Was established in 2011 as a Stanford University spin-out by a team of internationally-renown Next Generation Sequencing (NGS) thought leaders to provide advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and cancer immunotherapies by providing more comprehensive molecular data bout each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample The Personalis Clinical Laboratory in Menlo Park, Califonria is GxP aligned as well as CLIA’88-certified and CAP-accredited.

On 10 June 2020 Personalis, Inc announced a partnership with Berry Genomics with plans to expand operations in PRC with a wholly-owned subsidiary in Shanghai. Berry will provide sequencing services and local support to Personalis operation in Shanghai. Personalis, Inc was granted approval for a business license for Shanghai Personalis Biotechnology Co, LTD on 15 October 2020. The expansion to China includes buildout of a laboratory operation for local customers to use its ImmunoID Next Platform, a commercial team to support local customers and general and administrative functions.

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

We at Singh Biotechnology (SBT) are interested in meeting with you to exploring possible opportunities for partnering/in-licensing/scientific collaboration.

SBT is a start-up biotech company established in 2014. We discover/develop unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune, ophthalmological, and viral diseases by leveraging our propriety novel technology platform. Using this technology platform SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest that play an important role in the pathogenesis of disease(s). Our lead therapeutic (SBT-100) is a bi-specific sdAbs that specifically targets and inhibits intracellular KRAS and signal transducer and activator of transcription 3 (STAT3) proteins.